New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
Amarin presented new post-hoc data from the REDUCE-IT trial at the European Atherosclerosis Society Congress, showing that risk-weighted apoB (RW-apoB) better identifies residual cardiovascular risk in statin-treated patients than traditional biomarkers. The analysis of 3,485 placebo-arm participants found RW-apoB levels were approximately 30% higher than measured apoB, suggesting underrecognition of lipid-associated risk. RW-apoB demonstrated superior risk prediction compared to LDL-C, non-HDL-C, and standard apoB.
Key figures
- Rw apob vs apob
- 30% higher
- Vascepa prescriptions
- 25 million
- Median follow up years
- 4.9
- Placebo arm participants
- 3485
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.